ECONOMIC AND HUMANISTIC BURDEN OF IDIOPATHIC PULMONARY FIBROSIS: A SYSTEMATIC LITERATURE REVIEW
Author(s)
Mandeep Kaur Bhatia, MPharm1, Rachel Chu, MSc2, Liga Bennetts, PhD2, Wendy Zhong, PhD3, Aditi Desai, PharmD3, Clement Acheampong, BPharm, MPH3, Clement Acheampong, BPharm, MPH4, Aaron Carabajal-Johnson, PharmD, MS3.
1Amaris Consulting, Toronto, ON, Canada, 2Amaris Consulting, Montreal, QC, Canada, 3Bristol Myers Squibb, Princeton, NJ, USA, 4Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
1Amaris Consulting, Toronto, ON, Canada, 2Amaris Consulting, Montreal, QC, Canada, 3Bristol Myers Squibb, Princeton, NJ, USA, 4Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
OBJECTIVES: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing form of interstitial lung disease of unknown etiology that imposes a substantial burden on patients. As the treatment landscape continues to evolve, there is a need to consolidate the latest evidence. This systematic literature review aimed to synthesize evidence on the economic and humanistic burden of IPF.
METHODS: Embase, MEDLINE, MEDLINE In-Process, and EconLit were searched from January 2004 to October 2025 for observational studies reporting the humanistic or economic burden of IPF in patients ≥18 years, supplemented by gray literature.
RESULTS: Eighty studies assessed the humanistic burden of IPF, utilizing HRQoL measures including SGRQ (n=39 studies), EQ-5D (n=20), SF-36 (n=18), K-BILD (n=16), and HADS (n=15). Mean SGRQ total score ranged from 23.9-68.77 (n=31; 0-100, higher score: greater impairment), while mean EQ-5D index score varied from 0.62-0.79 (n=11; 0-1, 1: perfect health). Mean SF-36 PCS and MCS ranged from 29.4-52.4 and 43.0-56.8 (both n=7), respectively, and mean K-BILD total score from 48.2-73.1 (n=12; all 0-100, higher score: better health), indicating poor HRQoL. Across 4 studies, 8.6%-52% of patients had HADS-depression scores >8 and 8.8%-41% had HADS-anxiety scores >8, reflecting clinically relevant emotional and psychological burden. Sixty-five studies examined the economic burden. Total estimated annual direct costs (all-cause/respiratory/IPF-related) per patient ranged from US$10,124 (2012) to US$147,072 (2019) in the USA (n=9) and €4632 (2007; Spain) to €34,700 (not reported; Germany) in 4 European countries (France, Spain, Germany, Finland; n=7). Total annual healthcare cost was CA$8267 (2016) and CA$65,697 (2017) in 2 Canadian studies. Hospitalizations and IPF-related medication costs were key cost drivers. Annual productivity loss costs per patient were estimated at CA$11,737 in Canada (2017) and £11,378 in the UK (2011).
CONCLUSIONS: IPF is associated with poor HRQoL and high economic burden driven by hospitalizations and medication costs, highlighting continued unmet need.
METHODS: Embase, MEDLINE, MEDLINE In-Process, and EconLit were searched from January 2004 to October 2025 for observational studies reporting the humanistic or economic burden of IPF in patients ≥18 years, supplemented by gray literature.
RESULTS: Eighty studies assessed the humanistic burden of IPF, utilizing HRQoL measures including SGRQ (n=39 studies), EQ-5D (n=20), SF-36 (n=18), K-BILD (n=16), and HADS (n=15). Mean SGRQ total score ranged from 23.9-68.77 (n=31; 0-100, higher score: greater impairment), while mean EQ-5D index score varied from 0.62-0.79 (n=11; 0-1, 1: perfect health). Mean SF-36 PCS and MCS ranged from 29.4-52.4 and 43.0-56.8 (both n=7), respectively, and mean K-BILD total score from 48.2-73.1 (n=12; all 0-100, higher score: better health), indicating poor HRQoL. Across 4 studies, 8.6%-52% of patients had HADS-depression scores >8 and 8.8%-41% had HADS-anxiety scores >8, reflecting clinically relevant emotional and psychological burden. Sixty-five studies examined the economic burden. Total estimated annual direct costs (all-cause/respiratory/IPF-related) per patient ranged from US$10,124 (2012) to US$147,072 (2019) in the USA (n=9) and €4632 (2007; Spain) to €34,700 (not reported; Germany) in 4 European countries (France, Spain, Germany, Finland; n=7). Total annual healthcare cost was CA$8267 (2016) and CA$65,697 (2017) in 2 Canadian studies. Hospitalizations and IPF-related medication costs were key cost drivers. Annual productivity loss costs per patient were estimated at CA$11,737 in Canada (2017) and £11,378 in the UK (2011).
CONCLUSIONS: IPF is associated with poor HRQoL and high economic burden driven by hospitalizations and medication costs, highlighting continued unmet need.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE260
Topic
Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)